Benzinga | Aug 4, 2021 06:53AM EDT

TherapeuticsMD Q2 EPS $(0.11), Inline, Sales $23.00M Beat $22.11M Estimate

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 42.11 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $23.00 million which beat the analyst consensus estimate of $22.11 million by 4.03 percent. This is a 114.94 percent increase over sales of $10.70 million the same period last year.